Group 1: Company Overview and Strategy - The Chairman introduced the company's competitive advantages and future development strategies, emphasizing the importance of product quality and brand promotion [2] - The company plans to achieve significant growth in product shipments by the second half of 2025, aiming to enter the top market share within three years [2] Group 2: Product Development and Market Potential - In 2025, the company aims to complete the development and production of over ten key products, including Jian'er Pills and Wujihuai Feng Pills [3] - The total market capacity for the 125 product approvals from Xinxin Pharmaceutical exceeds 15 billion RMB, with expectations for substantial incremental growth [3] Group 3: E-commerce Growth - The company has established a 140-member e-commerce operations team, achieving approximately 50% annual growth in online business over the past five years [3] - Notable products in the personal care category have seen significant sales increases, contributing to the overall growth of the e-commerce segment [3] Group 4: Mergers and Acquisitions - The company has a history of successful acquisitions, including the purchase of Jiangxi Diwei Pharmaceutical in 2017, which resulted in multiple-fold revenue growth for acquired products [4] - Future acquisition strategies will focus on specialty drugs and significant products in niche markets, aiming to influence the company's direction over the next 5 to 10 years [4] - The company is actively monitoring potential acquisition targets that align with its strategic goals for 2024 [4]

证券代码：301331 证券简称：恩威医药 公告编号：2025-002 恩威医药股份有限公司 关于一致行动人取得金融机构增持贷款承诺暨增持公司 股份计划的公告 公司控股股东一致行动人成都杰威企业管理有限公司保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。本公司及董事会全体成员保证公告内容与信息披露义务 人提供的信息一致。 特别提示： 1、恩威医药股份有限公司（以下简称"公司"）控股股东成都恩威投资（集 团）有限公司（以下简称"恩威集团"）一致行动人成都杰威企业管理有限公司 （以下简称"成都杰威/增持主体"）基于对公司未来持续稳定发展的信心和长 期投资价值的认可，为增强投资者信心，成都杰威计划自本公告之日起 6 个月内， 通过集中竞价的方式增持公司A股股份。总体增持金额不低于人民币3,600万元， 不超过人民币 7,200 万元。 公司于近日收到公司控股股东恩威集团一致行动人成都杰威计划增持公司 股份的函，现将有关情况公告如下： 一、增持主体的基本情况 1 1、增持主体的名称：成都杰威企业管理有限公司，为公司控股股东一致行 动人。 2、增持主体已持有本公司股份的数量、占公司总 ...

Financial Performance - The estimated net profit for 2024 is projected to be 38 million CNY, a decrease of 55.97% compared to the previous year's profit of 86.31 million CNY[3] - The net profit after deducting non-recurring gains and losses is expected to be 35 million CNY, down 52.44% from 73.59 million CNY in the same period last year[3] Cost Factors - The decline in performance is attributed to increased costs from the company's equity incentive plan and amortization of intangible assets from the acquisition of Henan Xinxin Pharmaceutical[5] - Online promotion expenses have increased significantly to capture the market for Jieryin personal care products, contributing to the overall cost increase[5] Government Impact - Government subsidies have decreased, impacting the net profit by approximately 3 million CNY, a reduction of about 9.7 million CNY year-on-year[6]

Group 1: Company Overview and Competitive Advantages - The company has a strong brand and operational team that supports rapid growth in e-commerce, covering major platforms like Alibaba Health, JD Pharmacy, and Douyin [2] - The e-commerce business has achieved approximately 50% annual growth over the past five years, with 2023 revenue reaching 172 million CNY, accounting for 21.88% of total revenue [2] Group 2: Product Development and Market Strategy - The first batch of products from Henan Xinxin, including antiviral and detoxification oral liquids, has been launched, with sales meeting company expectations and several million CNY in orders already placed [3] - Production of Henan Xinxin products is outsourced to various manufacturers to leverage local advantages, with specific responsibilities assigned to different facilities [3] Group 3: Financial Health and Shareholder Returns - The company maintains a healthy cash flow and adheres to a stable dividend policy, having executed its post-listing dividend plan since inception [3] - The company is responsive to regulatory calls for active dividend distribution, aiming to share growth results with shareholders [3]

本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 恩威医药股份有限公司（以下简称"公司"或"本公司"）近日接到持股 5% 以上股东成都泽洪企业管理有限公司（以下简称"成都泽洪"）函告，获悉成都 泽洪所持本公司的部分股份被办理了质押。成都泽洪为公司持股 5%以上股东， 持有公司股份 12,884,140 股，占公司总股本的 12.52%。具体事项如下： | 股 | 是否 | 本次质押 | 占其 | 占公 | 是否 | 是否 | 质押起 | 质押到 | 质权 | 质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 东 | 为控 | 数量 | 所持 | 司总 | 为限 | 为补 | 始日 | 期日 | 人 | 押 | | 名 | 股股 | （股） | 股份 | 股本 | 售股 | 充质 | | | | 用 | | 称 | 东或 | | 比例 | 比例 | （如 | 押 | | | | 途 | | | 第一 | | | | 是， | | | | | ...

证券代码：301331 证券简称：恩威医药 公告编号：2024-068 恩威医药股份有限公司 关于持股 5%以上股东部分股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 恩威医药股份有限公司（以下简称"公司"或"本公司"）近日接到持股 5% 以上股东成都瑞进恒企业管理有限公司（以下简称"成都瑞进恒"）函告，获悉 成都瑞进恒所持本公司的部分股份被办理了质押。成都瑞进恒为公司持股 5%以 上股东，持有公司股份 12,884,140 股，占公司总股本的 12.52%。具体事项如下： | 股 | 是否 | 本次质押 | 占其 | 占公 | 是否 | 是否 | 质押起 | 质押到 | 质权 | 质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 东 | 为控 | 数量 | 所持 | 司总 | 为限 | 为补 | 始日 | 期日 | 人 | 押 | | 名 | 股股 | （股） | 股份 | 股本 | 售股 | 充质 | | | | 用 ...

证券代码：301331 证券简称：恩威医药 公告编号：2024-067 恩威医药股份有限公司 关于 2023 年限制性股票激励计划第一个归属期 归属结果暨股份上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次限制性股票归属日：2024 年 11 月 12 日。 2、本次归属股票数量：134.4787 万股，占目前公司股本总额的 1.3070%。 3、本次归属限制性股票人数：108 人。 4、本次归属的限制性股票无限售安排，股票上市后即可流通，激励对象为 董事、高级管理人员的按照相关规定执行。 恩威医药股份有限公司（以下简称"公司"、"本公司"或"恩威医药"） 于 2024 年 10 月 23 日召开第三届董事会第五次会议和第三届监事会第五次会议， 审议通过了《关于 2023 年限制性股票激励计划第一期归属条件成就的议案》。 近日，公司办理了 2023 年限制性股票激励计划第二类限制性股票第一个归属期 归属股份的登记工作，现将相关事项公告如下： 一、股权激励计划实施情况概要 （一）股权激励计划简介 公司于 2023 年 9 月 ...

证券代码：301331 证券简称：恩威医药 公告编号：2024-066 恩威医药股份有限公司 关于全资子公司取得换发的《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 恩威医药股份有限公司（以下简称：公司）全资子公司河南信心药业有限公司（以 下简称：信心药业）于近日取得了河南省药品监督管理局换发的《药品生产许可证》， 现将有关情况公告如下： 一、换发的《药品生产许可证》基本信息 企业名称：河南信心药业有限公司 注册地址：郑州市二七区嵩山南路 81 号嵩山园区综合楼南楼第五层楼 编 号：豫 20150079 分类码：AzBz 生产地址和生产范围： 郑州市陇海中路 56 号：片剂，颗粒剂，散剂，丸剂(大蜜丸、水蜜丸、水丸、浓 缩丸、蜡丸)，合剂(口服液)，糖浆剂，煎膏剂(含中药前处理及提取)***四川省成都市 双流区双华路三段 458 号(受托生产企业为四川恩威制药有限公司)前处理车间中药前 处理提取生产线、制剂车间合剂生产线：清热解毒口服液(每支装 10ml；国药准字 Z41021003)；清肝利胆口服液(每支装 10ml；国药准字 Z1 ...

Financial Performance - Revenue for Q3 2024 was CNY 172,191,555.13, a decrease of 1.40% year-over-year[3] - Net profit attributable to shareholders was CNY 4,087,519.85, down 54.45% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was CNY 5,268,576.05, a decline of 30.65% year-over-year[3] - Basic earnings per share for Q3 2024 was CNY 0.0414, a decrease of 52.58% from the previous year[3] - Total operating revenue for Q3 2024 was CNY 560,341,100.40, a decrease of 1.0% from CNY 569,885,071.76 in the same period last year[16] - Net profit for Q3 2024 was CNY 22,021,962.58, a significant decline of 69.8% compared to CNY 72,934,990.11 in Q3 2023[16] - Basic earnings per share decreased to CNY 0.2183 from CNY 0.7089 in the previous year, reflecting a drop of 69.1%[17] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,422,894,551.73, an increase of 6.38% from the end of the previous year[3] - Total assets increased to CNY 1,422,894,551.73, up 6.4% from CNY 1,337,497,679.93 at the end of the previous year[15] - Total liabilities rose to CNY 400,930,413.44, an increase of 70.9% compared to CNY 234,311,773.52 in the same period last year[15] - Shareholders' equity attributable to the parent company was CNY 1,021,964,138.29, down 7.36% from the previous year[3] - The company's total equity decreased to CNY 1,021,964,138.29, down 7.4% from CNY 1,103,185,906.41 year-over-year[15] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 71,464,477.74, an increase of 42.25% compared to the same period last year[7] - Operating cash inflow for the period was CNY 567,084,978.47, an increase of 3.8% compared to CNY 547,985,308.34 in the previous period[18] - Net cash outflow from operating activities was CNY 495,620,500.73, slightly decreased from CNY 497,747,218.30 in the previous period[19] - Net cash flow from operating activities was CNY 71,464,477.74, up 42.2% from CNY 50,238,090.04 in the previous period[19] - Cash inflow from financing activities was CNY 241,800,000, with a net cash flow of CNY 71,632,248.40, reversing from a net outflow in the previous period[19] - The ending cash and cash equivalents balance was CNY 365,428,864.02, an increase from CNY 324,470,029.93 in the previous period[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 6,527[8] - The top ten shareholders held a combined 28.90% of shares, with Chengdu Enwei Investment (Group) Co., Ltd. holding 29,733,200 shares[8] - The company has a total of 67.83% of shares controlled by a group of shareholders acting in concert, indicating a strong ownership structure[9] - The top ten shareholders include several investment partnerships, with the largest holding being 1,264,912 shares, representing 1.23% of total shares[11] - The company has not reported any changes in the number of preferred shareholders or significant changes in restricted shares[12] Expenses - Total operating costs increased to CNY 534,869,746.20, up 7.5% from CNY 497,376,667.73 year-over-year[16] - Research and development expenses were CNY 5,770,697.03, a decrease of 61.4% from CNY 14,966,254.02 in the previous year[16] - Sales expenses increased to CNY 187,705,109.10, up 17.8% from CNY 159,371,926.26 year-over-year[16] - The company reported a significant increase in tax expenses to CNY 9,447,037.16, compared to CNY 7,600,231.62 in the same period last year[16] Asset Changes - The company reported a significant increase in construction in progress by 303.77% to CNY 35,605,470.48 due to increased investment in fundraising projects[7] - The company's cash and cash equivalents increased to ¥366,010,905.68 from ¥236,120,514.71, representing a growth of approximately 55.0%[13] - Accounts receivable rose to ¥104,098,324.83 from ¥93,095,689.67, indicating an increase of about 11.5%[13] - The total current assets reached ¥864,538,310.27, up from ¥786,859,452.41, reflecting a growth of approximately 9.8%[13] - Long-term equity investments decreased to ¥330,447.34 from ¥373,989.35, showing a decline of about 11.6%[13] - The company's fixed assets decreased to ¥209,539,965.27 from ¥220,638,376.27, a reduction of approximately 5.0%[13] - The company's intangible assets decreased to ¥137,396,425.04 from ¥148,043,809.24, representing a decline of about 7.2%[13] - The company reported a significant increase in prepayments, rising to ¥25,311,174.63 from ¥14,911,422.66, which is an increase of approximately 69.5%[13] - Cash paid for purchasing fixed assets and other long-term assets was CNY 46,088,085.94, significantly higher than CNY 15,592,083.55 in the previous period[19] - Cash paid for employee compensation was CNY 148,781,353.45, slightly increased from CNY 147,909,484.90 in the previous period[19] - Cash paid for taxes was CNY 60,845,460.61, down from CNY 65,284,660.61 in the previous period[19]

证券代码：301331 证券简称：恩威医药 公告编号：2024-064 恩威医药股份有限公司 关于作废部分已授予但尚未归属的第二类限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 恩威医药股份有限公司（以下简称"公司"、"本公司"或"恩威医药"）于 2024 年 10 月 23 日召开第三届董事会第五次会议和第三届监事会第五次会议，审议通 过了《关于作废部分已授予但尚未归属的第二类限制性股票的议案》。现将有关 事项说明如下： 一、公司 2023 年限制性股票激励计划已履行的相关审批程序 （一）2023 年 9 月 26 日，公司召开第二届董事会第十五次会议，审议通过 了《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公 司<2023 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大 会授权董事会办理股权激励相关事宜的议案》等议案，公司独立董事就本激励计 划发表了独立意见，律师、独立财务顾问出具了相应的意见与报告。 同日，公司召开第二届监事会第十四次会议，审议通过了《关于公司<2023 年限制性股票激励计划 ...